| Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP) 期刊论文 Science Bulletin, 2021, 卷号: 66, 期号: 15 作者: Ji L.; Song W.; Fang H.; Li W.; Geng J.; Wang Y.; Guo L.; Cai H.; Yang T.; Li H.; Yang G.; Li Q.; Liu K.; Li S.; Liu Y.; Shi F.; Li X.; Gao X.; Tian H.; Ji Q.; Su Q.; Zhou Z.; Wang W.; Zhou Z.; Li X.; Xu Y.; Ning Z.; Cao H.; Pan D.; Yao H.; Lu X.; Jia W. 收藏  |  浏览/下载:39/0  |  提交时间:2021/09/01 Carfloglitazar Chiglitazar Glycemic control Insulin resistance PPAR pan-agonist Type 2 diabetes |